Cargando…

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer

Osimertinib, a third-generation EGFR-TKI, has nowadays been applied to non-small cell lung cancer harboring activated EGFR mutation with or without T790M, but ultimately develop resistance to this drug. Here we report a novel mechanism of acquired resistance to osimertinib and the reversal of which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murakami, Yuichi, Kusakabe, Daiki, Watari, Kosuke, Kawahara, Akihiko, Azuma, Koichi, Akiba, Jun, Taniguchi, Masahiko, Kuwano, Michihiko, Ono, Mayumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148303/ https://www.ncbi.nlm.nih.gov/pubmed/35643725 http://dx.doi.org/10.1038/s41598-022-12995-8

Ejemplares similares

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
por: Watari, Kosuke, et al.
Publicado: (2016)

NDRG1 activates VEGF-A-induced angiogenesis through PLCγ1/ERK signaling in mouse vascular endothelial cells
por: Watari, Kosuke, et al.
Publicado: (2020)

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
por: Azuma, Koichi, et al.
Publicado: (2014)

Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages
por: Watari, Kosuke, et al.
Publicado: (2014)

N-myc Downstream Regulated Gene 1 (NDRG1) Promotes Metastasis of Human Scirrhous Gastric Cancer Cells through Epithelial Mesenchymal Transition
por: Ureshino, Hiroki, et al.
Publicado: (2012)

Oncogenic Y‐box binding protein‐1 as an effective therapeutic target in drug‐resistant cancer
por: Kuwano, Michihiko, et al.
Publicado: (2019)

The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes
por: Murakami, Yuichi, et al.
Publicado: (2019)

Impaired differentiation of macrophage lineage cells attenuates bone remodeling and inflammatory angiogenesis in Ndrg1 deficient mice
por: Watari, Kosuke, et al.
Publicado: (2016)

CDCP1 promotes compensatory renal growth by integrating Src and Met signaling
por: Kajiwara, Kentaro, et al.
Publicado: (2021)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer
por: Shibata, Tomohiro, et al.
Publicado: (2018)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Structural Requirements for Cub Domain Containing Protein 1 (CDCP1) and Src Dependent Cell Transformation
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2012)

KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer
por: Park, Jung-Jin, et al.
Publicado: (2012)

SRC kinase activator CDCP1 promotes hepatocyte growth factor–induced cell migration/invasion of a subset of breast cancer cells
por: Kawase, Naoyuki, et al.
Publicado: (2022)

Heparin‐binding Epidermal Growth Factor‐like Growth Factor: p91 Activation, Induction of Plasminogen Activator/Plasminogen Activator Inhibitor, and Tubular Morphogenesis in Human Microvascular Endothelial Cells
por: Ushiro, Shin, et al.
Publicado: (1996)

Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer
por: Ono, Takeharu, et al.
Publicado: (2020)

Co‐expression of Thymidine Phosphorylase and Heme Oxygenase‐1 in Macrophages in Human Malignant Vertical Growth Melanomas
por: Torisu‐Itakura, Hitoe, et al.
Publicado: (2000)

High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
por: Yoshimura, Akihiro, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer
por: Yang, Lifang, et al.
Publicado: (2015)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer
por: Harrington, Brittney S., et al.
Publicado: (2020)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer
por: Cuda, Tahleesa J., et al.
Publicado: (2021)

Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers
por: Donahue, Katelyn L., et al.
Publicado: (2022)

Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma
por: Ono, Takeharu, et al.
Publicado: (2017)

Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma
por: Kryza, Thomas, et al.
Publicado: (2020)

Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma
por: Lin, Zhiying, et al.
Publicado: (2022)

Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment
por: Wong, Sze‐Ching, et al.
Publicado: (2023)

Cooperative Roles of Hepatocyte Growth Factor and Plasminogen Activator in Tubular Morphogenesis by Human Microvascular Endothelial Cells
por: Morimoto, Akio, et al.
Publicado: (1994)

Dual Pathways to Tubular Morphogenesis of Vascular Endothelial Cells by Human Glioma Cells: Vascular Endothelial Growth Factor/Basic Fibroblast Growth Factor and Interleukin‐8
por: Wakabayashi, Yukihiro, et al.
Publicado: (1995)

Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
por: Takeda, Takayuki, et al.
Publicado: (2017)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

Hepatic stem cells with self-renewal and liver repopulation potential are harbored in CDCP1-positive subpopulations of human fetal liver cells
por: Zhang, Ran-Ran, et al.
Publicado: (2018)

Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
por: Yeh, Chen-Yun, et al.
Publicado: (2011)

The assessment of correlation and prognosis among (18)F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients
por: Kaida, Hayato, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cv6cfcp31216gr73vpune9tda8